Enlivex Therapeutics Ltd (IL:ENLV)
TASE:ENLV
ENLV Stock Chart & Stats
290.70
<0.01(0.04%)
At close: 4:00 PM EST
290.70
<0.01(0.04%)
Day’s Range― - ―
52-Week Range213.20 - 682.90
Previous CloseN/A
Volume17.58K
Average Volume (3M)48.96K
Market Cap
₪683.96M
Enterprise Value22.00M
Total Cash (Recent Filing)₪5.87M
Total Debt (Recent Filing)₪641.00K
Price to Earnings (P/E)<0.1
Beta0.27
Next Earnings
May 22, 2026EPS Estimate
-24.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-43.39
Shares Outstanding237,381,500
10 Day Avg. Volume46,403
30 Day Avg. Volume48,957
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪6,176.73Price Target Upside2024.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-100.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtEnlivex’s debt-to-equity is near zero, giving the company low financial risk and greater flexibility to fund R&D or shore up operations without high interest obligations. This durable low-leverage profile reduces bankruptcy risk and supports runway extension while clinical programs advance.
FDA IND Clearance For Phase 2b Allocetra In Knee OAReceiving IND clearance for a global, randomized Phase 2b trial advances Allocetra toward late-stage validation in a large, aging-market indication. This regulatory milestone de-risks development pathway and strengthens long-term commercial potential if trials confirm efficacy and safety.
Substantial Treasury Assets Bolster LiquidityLarge treasury holdings provide material liquidity and strategic optionality: they can fund trials, support convertible financings, repurchases or token strategies without immediate dilutive equity raises. This non-operating capital base can sustainably back near-term development needs.
Bears Say
Negligible Revenue; Operating LossesEnlivex remains a clinical-stage R&D company with essentially no commercial revenues and persistent operating losses, meaning intrinsic cash generation is weak. Long-term value therefore depends on clinical success or continued external funding rather than sustainable product sales.
Consistent Negative Operating Cash FlowThe company has experienced multi-year operating cash outflows, indicating cash burn that necessitates external financing. Until operating cash flow turns positive, Enlivex’s development programs and corporate plans rely on asset monetization or financings, which can dilute shareholders or restrict strategy.
Balance-sheet Volatility From One-time GainsA dramatic equity jump driven by unrealized treasury gains undermines confidence in balance-sheet stability and earnings quality. Such non-operating swings can be illiquid or volatile, making the financial position contingent on market conditions rather than steady operational improvement.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was 213.20 and its highest was 682.90 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is ₪683.96M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is May 22, 2026 which is in 41 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on Mar 25, 2026. The company reported -43.389 earnings per share for the quarter, missing the consensus estimate of -26.094 by -17.295.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate is -24.88.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 237,381,500 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -43.389 in its last earnings report, missing expectations of -26.094. Following the earnings report the stock price went up 14.226%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in IL:ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪6,176.73 (2024.78% Upside)
₪6,176.73 (2024.78% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.26%
12-Months-Change
Fundamentals
Return on Equity
-62.91%
Trailing 12-Months
Asset Growth
8304.66%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
ENLV Stock 12 Month Forecast
Average Price Target
6,176.73
▲(2024.78% Upside)